Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

33
Earnings deluge, what could be best reading on economy in four years in week ahead

2018-07-20 cnbc
Earnings are expected from a third of S&P 500 companies in the week ahead, and there will also be an important report card on the economy, with second-quarter GDP expected to be the strongest in four years.
LMT DB TXN XOM UAA HA RDSB RDSA MPC NOC BSX GM.WS.A GM.WS.B JNPR GM.WS.C GM RYDAF FSLR CIT EA RDS.B RDS.A GILD VLO UTX SYF NSC CMG UA AVY TSCO FFIV VIRT RYDBF LVS GM.WSB

2
CIT / CIT Group, Inc. (The) FORM 8-K (Current Report)

2018-07-17 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CIT

7
Blucora Announces the Appointment of Carol Hayles and John MacIlwaine to the Board of Directors

2018-07-11 globenewswire
IRVING, Texas, July 11, 2018 (GLOBE NEWSWIRE) -- Blucora, Inc. (NASDAQ:BCOR), a leading provider of technology-enabled financial solutions to consumers, small businesses and tax professionals, today announced the addition of Carol Hayles and John MacIlwaine to the Company’s Board of Directors. Both appointments were effective as of July 10, 2018.
C.WSA C C.PRL C.PRJ C.PRK C.PRG GDOT C.PRC BCOR C.WS.B C.PRPCL CGBBW C.WS.A C.PRP C.PRU CIT C.PRS

235
Stocks To Watch: A New Beverage Giant Steps Out

2018-07-07 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GNK GIS JWN CIT EDR DUKH AMC ENTG PDYPF INFY KORS MSFT OXY HELE LMT KKR TM KLIC WFC.PRL WFC.PRJ LB MPC BAC WFC.PRT ZION WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN CCL KO WFC.PRY INTC WDFC WFC.PRX WFC.PRW WFC.PRV LUV NCLH DUK VRCA HMC OTC JPM ZUMZ TSLA ESPR TTM TOL HA RCL UAL KEY CATO CHRA ALGT VLKAY OSTK RNLSY BAC NJR OTEX FAST BKE CCL MDLZ HOG CMI PNC INFY AHBIF FOXA WFCNP RNSDF JBLU USX NEW WIMHY ALK GS MYL JEF GRKGF DAL DIS ABEV WFC WIMHF WFC.WS BUD C CMCSA COST BCNQY WMH SNY AVLR PEP SNE

57
Oppenheimer Says Financials Are Cheap: 4 to Buy Now

2018-07-05 247wallst
By any measure, the financial sector is one of the cheapest of all in the S&P 500, and despite some very positive tailwinds, the sector has lagged dramatically this year. The good news for investors looking to add or increase positions in the sector is that with the stress tests out of the way and mostly positive, and the direction of interest rates pointing higher, now may be the best time to buy some of the top companies.
C.WSA GS.PRB GS.PRA BAC GS C.WS.B GLSSP C.WS.A C.PRP C.PRU CIT C.PRS JBK BAC C C.PRL GSC GS.PRICL C.PRJ TFG C.PRK C.PRG GSJ C.PRC GS.PRJ GS.PRI C.PRPCL GS.PRD CGBBW GS.PRC GJS GS.PRN GS.PRK

121
Top Analyst Upgrades and Downgrades: Accenture, Ally, Diageo, Harley-Davidson, KB Home, NetApp, Nike, Sirius XM, Walgreens and More

2018-06-29 247wallst
Stocks were looking for a stronger open on Friday for the last trading day of the second quarter of 2018. That said, the year-to-date performance has been down 2% for the Dow Jones industrial average and a 1.5% gain for the S&P 500. The trend of buying the dips has not worked as well as it has in prior years, and many investors have been considering how they want their investments positioned for the longer term.
MRVL KBH DB MS.PRE MS.PRF MS.PRG HOG MS.PRA CISN ALLY.PRA XLRN CJ NKE MS.PRI ALLY MS.PRK ACN TRI NTAP MS DGE DGE CIT DEO

21
CIT / CIT Group, Inc. (The) FORM 8-K (Current Report)

2018-06-28 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CIT

83
U.S. business borrowing for equipment flat in May - ELFA

2018-06-25 reuters
(Reuters) - U.S. companies’ borrowing to spend on capital investment was little changed in May from a year earlier, the Equipment Leasing and Finance Association (ELFA) said.
CATR CAT VOLVF CAJ VZ VOLVY VOLAF CIT VLVLY VZA

145
3 Bank Stocks to Buy After the Fed’s Stress Tests | InvestorPlace

2018-06-22 investorplace
It’s a controversial process that all financial institutions anxiously await every year. Since the disaster of the 2008 crisis, the U.S. Federal Reserve imposes a stress test on major banks to ensure their viability under recessionary pressures. Fortunately for all concerned, the assessed institutions passed, providing positive sentiment toward bank stocks.
BAC WTFCM ZION DB CMA JPM NYTAB WTFCW WTFPP WTFC CIT

242
Banks Clear Fed's Stress Test: Bigger Payout to Follow?

2018-06-22 zacks
The Federal Reserve’s first round of stress test this year reflects that the nation’s biggest banks are ‘well capitalized.’ On Thursday, the Fed released the Dodd-Frank Act supervisory stress test 2018 (DFAST 2018) results. It shows that all 35 banks (including the U.S. units of foreign banks with $50 billion or more in total consolidated assets) are adequately capitalized to survive under tremendously difficult economic conditions.
WFCNP ZIONW CMA.WS MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG ZB.PRF MS.PRA ZB.PRA CMPWW BAC WFC.PRT ZBK WFC.PRR ZION WFC.PRQ WFC.PRP WFC.PRO WFC.PRN MS WFC.PRY WFC.PRX WFC.PRW CIT WFC.PRV WFC WFC.WS BAC C CMA ZB.PRG MS.PRI ZB.PRH MS.PRK ZIONZ

185
Wall Street clears stress test hurdle with ample capital

2018-06-22 malaymail
WASHINGTON, June 22 — Big banks cleared the first hurdle of this year’s US stress tests as the Federal Reserve found all 35 lenders examined could withstand a severe economic downturn, though Goldman Sachs Group Inc trailed the rest of Wall Street in a key measure of leverage.
BCS GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA 83SF ZBK GLSSP UGLD 83SK MS CIT STT JBK DSLV CMA CSSLF TFG GS.PRJ GS.PRI MS.PRI GS.PRD MS.PRK GS.PRC GS.PRN GS.PRK BCS.PRD ZIONW BCS.PRC CMA.WS DB STT.PRC BCS.PRA DGLD STT.PRE STT.PRD STT.PRG ZB.PRF CS ZB.PRA CMPWW GS ZION 47MC VIIX GSC GS.PRICL VIIZ GSJ CSGKF BCS.PR ZB.PRG ZB.PRH ZIV USLV TVIX GJS ZIONZ XIV

75
Biggest Banks Pass Fed’s Stress Tests - The New York Times

2018-06-21 nytimes
The nation’s biggest banks are strong enough to continue lending if the economy plunges into a severe downturn, an assessment by the Federal Reserve on Thursday that could fuel Wall Street’s calls to further relax financial regulations.
WFCNP ZIONW MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG ZB.PRF MS.PRA ZB.PRA WFC.PRT ZBK WFC.PRR ZION WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY MS WFC.PRX WFC.PRW CIT WFC.PRV WFC WFC.WS NYTAB ZB.PRG MS.PRI ZB.PRH MS.PRK ZIONZ

185
Wall Street Clears Stress Test Hurdle With Ample Capital

2018-06-21 theedgemarkets
(June 22): Big banks cleared the first hurdle of this year’s U.S. stress tests as the Federal Reserve found all 35 lenders examined could withstand a severe economic downturn, though Goldman Sachs Group Inc. trailed the rest of Wall Street in a key measure of leverage.
BCS GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA 83SF ZBK GLSSP UGLD 83SK MS CIT STT JBK DSLV CMA CSSLF TFG GS.PRJ GS.PRI MS.PRI GS.PRD MS.PRK GS.PRC GS.PRN GS.PRK BCS.PRD ZIONW BCS.PRC CMA.WS DB STT.PRC BCS.PRA DGLD STT.PRE STT.PRD STT.PRG ZB.PRF CS ZB.PRA CMPWW GS ZION 47MC VIIX GSC GS.PRICL VIIZ GSJ CSGKF BCS.PR ZB.PRG ZB.PRH ZIV USLV TVIX GJS ZIONZ XIV

185
Wall Street Clears Stress Test Hurdle With Ample Capital - Bloomberg

2018-06-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BCS GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA 83SF ZBK GLSSP UGLD 83SK MS CIT STT JBK DSLV CMA CSSLF TFG GS.PRJ GS.PRI MS.PRI GS.PRD MS.PRK GS.PRC GS.PRN GS.PRK BCS.PRD ZIONW BCS.PRC CMA.WS DB STT.PRC BCS.PRA DGLD STT.PRE STT.PRD STT.PRG ZB.PRF CS ZB.PRA CMPWW GS ZION 47MC VIIX GSC GS.PRICL VIIZ GSJ CSGKF BCS.PR ZB.PRG ZB.PRH ZIV USLV TVIX GJS ZIONZ XIV

44
Fed says all banks met minimum capital requirements after stress tests - MarketWatch

2018-06-21 marketwatch
All of the banks tested by the Federal Reserve met the regulatory minimums for capital after being tested for the impact of a severe recession, the central bank announced Thursday.
CMA.WS CMA CIT CMPWW

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 125581801